<--GAT-->

Expedited ART Significantly Lowers Viral Load in HIV Patients

by Brenda Mooney

August 16, 2017

By Brenda L. Mooney

BETHESDA, MD—When it comes to treating acute HIV infection, sooner is better, noted a new study led by U.S. military researchers.

The study, published in the Journal of the International AIDS Society, compared viral load in patients during acute HIV infection. The researchers, led by the U.S. Military HIV Research Program (MHRP), determined that those who began antiretroviral therapy (ART) immediately had significantly lower viral loads vs. those for whom therapy was delayed.1

The study team said it embarked on the review because, while the extent of viral replication during acute HIV infection (AHI) influences HIV disease progression, how ART affects viral load during AHI has not been fully explored.

This analysis reviewed viral load data obtained during the first year of HIV infection from two MHRP-led cohort studies in Thailand: the RV217 study and the RV254 study.

The first study, RV217, involved a prospective cohort of individuals at high risk for HIV who are regularly screened for AHI. The authors pointed outthat ART is initiated according to standard of care at local health centers, and none in the analysis had begun ART.

The RV254 cohort, meanwhile, enrolls patients diagnosed with AHI at an HIV testing center that has routine AHI screening, and those are offered immediate ART.

Results indicated that HIV replication is halted soon after ART initiation, resulting in a stark difference in viral load trajectories between the treated and untreated volunteers. The study pointed out that by day 12 of the study—four days after ART began in RV254 volunteers—the untreated group had a 2.7-fold higher viral load level compared to those treated.

Those increases burgeoned to 135-fold by day 30 and 1148-fold by day 120.

Predicted log viral load kinetics comparing RV217-untreated vs. RV254-treated acute HIV infection participants.The predicted values with a 95% confidence band are shown. The green and purple lines represent the upper and lower bounds of the 95% confidence intervals. The grey vertical line indicates the median start of treatment for RV254. Predicted log viral load means (95% confidence interval) for each study is given as follows: day 5 – RV217: 5.23 (4.87, 5.6), RV254: 5.21 (4.95, 5.48); day 10 – RV217: 6.14 (5.75, 6.54), RV254: 5.92 (5.78, 6.06); day 12 – RV217: 6.19 (5.78, 6.59), RV254: 5.76 (5.62, 5.9); day 30 – RV217: 4.89 (4.64, 5.14), RV254: 2.76 (2.64, 2.88); day 120 – RV217: 4.68 (4.48, 4.87), RV254: 1.62 (1.58, 1.67).

“Initiating ART in AHI dramatically changed the trajectory of viral load very early in the course of infection, which could have implications for reducing potential to transmit HIV and enhancing responses to future HIV remission strategies,” explained Jintanat Ananworanich, MD, PhD, MHRP’s Associate director for Therapeutics Research and protocol chair of RV254.

Background information in the articles explained that inhibiting viral replication infection prevents viral mutation, and reduces immune destruction, seeding of the latent HIV reservoir and immune activation.

“Initiating ART in AHI dramatically changed the trajectory of VL very early in the course of infection that could have implications for reducing transmission potential and enhancing responses to future HIV remission strategies,” the study concluded.

“There is an urgency to initiate ART when acute infection is identified,” added senior author Merlin Robb, MD. MHRP’s Clinical Deputy Director and senior author of the paper. “New and inexpensive strategies to engage and test individuals at high risk for HIV as well as immediate treatment access will be needed to improve the treatment of acute infection globally.”

  1. Ananworanich J, Eller LA, Pinyakorn S, Kroon E, Sriplenchan S, Fletcher JL, Suttichom D, Bryant C, Trichavaroj R, Dawson P, Michael N, Phanuphak N, Robb ML. Viral kinetics in untreated versus treated acute HIV infection in prospective cohort studies in Thailand. J Int AIDS Soc. 2017 Jun 26;20(1):1-7. doi: 10.7448/IAS.20.1.21652. PubMed PMID: 28691436.

Comments are closed here.


Related Articles

Physician Documents, Promotes Veteran Honor Guards in VA Hospices

PHILADELPHIA—Michelle Brassil, MD, had been warned when she began her fellowship at the Cpl. Michael J. Crescenz VA Medical Center’s Community Living Center in Philadelphia. “Don’t be surprised if you’re emotional,” her supervisor told her.... View Article

Lack of DoD/VA Decision-Maker Could Hamper EHR Implementation

WASHINGTON—Plans are moving ahead for VA’s 10-year, $16 billion effort to modernize its electronic health record system, but legislators still have questions about the project’s timeline and funding, as well as concerns about the project’s... View Article


U.S. Medicine Recommends


More From infectious disease

Infectious Disease

New Antibiotic Provides Powerful Option for Resistant Pneumonia, Skin Infections

A next-generation tetracycline, omadacycline could improve care for veterans with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI).

Infectious Disease

Prescribed Opioids Increase Risk of Pneumonia in Veterans

A study looking at whether taking prescribed opioids increased pneumonia risk in veterans with HIV vs. those without came to a disturbing conclusion: The likelihood is increased in both.

Infectious Disease

DHA Releases Interim Guidance for HIV Pre-Exposure Prophylaxis

The Defense Health Agency (DHA) has released interim guidance designed to optimize clinical use of human immunodeficiency virus (HIV) pre-exposure prophylaxis and reduce variability in access to prophylactic medication.

Infectious Disease

With Advancing Age, Veterans with HIV Face Novel Challenges

Thirty years ago, veterans with human immunodeficiency virus and their physicians focused on survival.

Infectious Disease

Could Bilirubin Measurements Predict, Prevent CV Events in HIV Patients?

For most people, mention of bilirubin, which is formed after the breakdown of red blood cells and is eliminated by the liver, elicits thoughts of jaundice—which occurs when the compound is too high.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up